Nasdaq · Biotech stocks database

RNA — Atrium Therapeutics Inc.

RNA (Atrium Therapeutics Inc.) stock: $8.95, $153.1M market cap, $263.9M cash, -$110.8M EV, $155.2M fully diluted market cap. Next expected readout: May-28. Lead program: ATR 1072 (Cardiac Glycogenosis), Phase 1/2. Data from Fully Diluted's biotech stocks database.

Share price

$8.95

Market cap

$153.1M

Cash

$263.9M

Enterprise value

-$110.8M

Balance sheet

Cash	$263.9M
Debt	$0.0M
Net cash	$263.9M
Enterprise value	-$110.8M
Basic shares	17.1M shares
Fully diluted shares	17.3M shares
Fully diluted market cap	$155.2M
Cash per share	$15.43

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading RNA daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jun 12 - Jul 24	ATR 1072	Phase 1/2	Cardiac Glycogenosis; Cardiomyopathy; Hypertrophic	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Lead drug	ATR 1072
Lead indication	Cardiac Glycogenosis
Lead phase	Phase 1/2
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07738107	Phase 1/2	Not yet recruiting	Sponsor	Atrium Therapeutics	—	Cardiac Glycogenosis; Cardiomyopathy; Hypertrophic	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Atrium Therapeutics on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	57,688	no change	0.04%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 714 stocks.

Subscribe to Compounding Ego